DK1153017T3 - Bicykliske forbindelser og deres anvendelse som integrinreceptorligander - Google Patents

Bicykliske forbindelser og deres anvendelse som integrinreceptorligander

Info

Publication number
DK1153017T3
DK1153017T3 DK00903864T DK00903864T DK1153017T3 DK 1153017 T3 DK1153017 T3 DK 1153017T3 DK 00903864 T DK00903864 T DK 00903864T DK 00903864 T DK00903864 T DK 00903864T DK 1153017 T3 DK1153017 T3 DK 1153017T3
Authority
DK
Denmark
Prior art keywords
optionally substituted
compounds
receptor ligands
integrin receptor
bicyclic compounds
Prior art date
Application number
DK00903864T
Other languages
Danish (da)
English (en)
Inventor
David Edward Clark
Paul Robert Eastwood
Neil Victor Harris
Clive Mccarthy
Andrew David Morley
Stephen Dennis Pickett
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903532.1A external-priority patent/GB9903532D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of DK1153017T3 publication Critical patent/DK1153017T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK00903864T 1999-02-16 2000-02-16 Bicykliske forbindelser og deres anvendelse som integrinreceptorligander DK1153017T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903532.1A GB9903532D0 (en) 1999-02-16 1999-02-16 Chemical compounds
US14144599P 1999-06-29 1999-06-29

Publications (1)

Publication Number Publication Date
DK1153017T3 true DK1153017T3 (da) 2006-07-17

Family

ID=26315145

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00903864T DK1153017T3 (da) 1999-02-16 2000-02-16 Bicykliske forbindelser og deres anvendelse som integrinreceptorligander

Country Status (11)

Country Link
US (1) US6593354B2 (cg-RX-API-DMAC7.html)
EP (1) EP1153017B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002537292A (cg-RX-API-DMAC7.html)
AT (1) ATE325105T1 (cg-RX-API-DMAC7.html)
AU (1) AU775208B2 (cg-RX-API-DMAC7.html)
CA (1) CA2362862A1 (cg-RX-API-DMAC7.html)
DE (1) DE60027700T2 (cg-RX-API-DMAC7.html)
DK (1) DK1153017T3 (cg-RX-API-DMAC7.html)
ES (1) ES2263447T3 (cg-RX-API-DMAC7.html)
PT (1) PT1153017E (cg-RX-API-DMAC7.html)
WO (1) WO2000049005A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01010231A (es) * 1999-04-12 2003-07-21 Aventis Pharma Ltd Compuestos heteroarilo biciclicos sustituidos como antagonistas de integrina.
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
GB0004686D0 (en) * 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
CA2430978C (en) 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
JP4676884B2 (ja) 2003-07-24 2011-04-27 第一三共株式会社 シクロヘキサンカルボン酸類
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
EP1737809B1 (en) * 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
DE102006021878A1 (de) * 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025637A (en) 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US4100168A (en) 1974-09-20 1978-07-11 Lilly Industries Ltd. 2,5 OR 2,6-Disubstituted benzoxazoles
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE69706407T2 (de) * 1996-03-29 2002-05-29 G.D. Searle & Co., Chicago META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
JPH10330369A (ja) 1997-04-04 1998-12-15 Sumitomo Pharmaceut Co Ltd 複素環化合物
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
GB9916374D0 (en) * 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
WO2000005223A2 (en) * 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitors

Also Published As

Publication number Publication date
JP2002537292A (ja) 2002-11-05
ES2263447T3 (es) 2006-12-16
EP1153017A1 (en) 2001-11-14
PT1153017E (pt) 2006-07-31
CA2362862A1 (en) 2000-08-24
AU775208B2 (en) 2004-07-22
WO2000049005A1 (en) 2000-08-24
AU2561700A (en) 2000-09-04
DE60027700D1 (de) 2006-06-08
EP1153017B1 (en) 2006-05-03
US6593354B2 (en) 2003-07-15
ATE325105T1 (de) 2006-06-15
US20020137782A1 (en) 2002-09-26
DE60027700T2 (de) 2007-05-03

Similar Documents

Publication Publication Date Title
PT1153017E (pt) Compostos biciclicos e sua utilizacao como ligandos do receptor de integrina
KR20050085991A (en) Compounds exhibiting thrombopoietin receptor agonism
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
WO2003024967A3 (en) Indolizines as kinase protein inhibitors
TNSN06203A1 (en) Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
NO20074368L (no) Syklopentapyridin- og tetrahydroquinolinderivater
TW200604183A (en) Triazole compounds and their use as metabotropic glutamate receptor antagonists
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
WO2008111604A1 (ja) 新規なベンジル(ヘテロサイクリックメチル)アミン構造を有するピリミジン化合物及びこれを含有する医薬
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
PE20090216A1 (es) Compuestos triazolil aminopirimidina
DE60121461D1 (de) Kondensierte pyridoindolderivate
MX2007007098A (es) Derivados de pirrol que tienen actividad antagonista del receptor crth2.
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
TR200101711T2 (tr) Antihistaminik spiro bileşikler.
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NZ519126A (en) Novel IL-8 receptor antagonists
YU39503A (sh) Derivati pirimidina
ATE375985T1 (de) Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten